Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion
Fierce Pharma
NOVEMBER 2, 2023
The third quarter marked a momentous one for Sarepta Therapeutics, bringing the long-anticipated launch of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Even before a potential label expansion, the gene therapy Elevidys has raked in around $69 million since its launch.
Let's personalize your content